Hepatology:人参皂苷Rg3恢复丙型肝炎病毒导致的线粒体动力学异常并抑制病毒繁殖

2017-05-31 MedSci MedSci原创

丙型肝炎病毒(HCV)改变线粒体动力学,而异常的线粒体动力学与持续性病毒感染和自然免疫被抑制相关。线粒体功能障碍也是直接作用抗病毒(DAA)治疗中的病理特征。尽管DAA疗效较好,但是在干扰素豁免方案治疗慢性丙型肝炎患者时偶尔会产生副作用,如疲劳、偏头痛和其他可能与线粒体功能障碍有关的病症。近日韩国学者发表研究性文章于Hepatology。本研究显示临床DAA类药物,包括索非布韦,可影响线粒体动力学

丙型肝炎病毒(HCV)改变线粒体动力学,而异常的线粒体动力学与持续性病毒感染和自然免疫被抑制相关。线粒体功能障碍也是直接作用抗病毒(DAA)治疗中的病理特征。尽管DAA疗效较好,但是在干扰素豁免方案治疗慢性丙型肝炎患者时偶尔会产生副作用,如疲劳、偏头痛和其他可能与线粒体功能障碍有关的病症。

近日韩国学者发表研究性文章于Hepatology。本研究显示临床DAA类药物,包括索非布韦,可影响线粒体动力学。为了对抗这些不良反应,研究者检测支持线粒体生理健康和自然免疫系统的人参皂甙是否可以调节HCV感染和DAA治疗诱导的异常线粒体动力学。

使用HCV细胞培养系统筛选出具有抗病毒活性的几种人参皂苷化合物。我们检测了人参皂甙在抗病毒疗效,线粒体跨膜电位的改变,线粒体异常分裂,上游信号传导和由HCV感染或DAA治疗引起的线粒体自噬过程中的作用。其中只有一种化合物人参皂甙Rg3(G-Rg3)显示出显著的抗HCV潜力。用G-Rg3处理HCV感染的细胞,可增加HCV核心蛋白介导的细胞质p21表达水平的降低。细胞质p21是增加细胞周期蛋白依赖性激酶1(CDK1)活性所必需的,其催化动力相关蛋白1(Drp1)Ser616位点磷酸化。 HCV诱导的线粒体分裂后的线粒体自噬也可被G-Rg3治疗所逆转。

G-Rg3抑制HCV繁殖,其抗病毒机制为恢复HCV诱导的Drp1介导的线粒体异常分裂过程,从而抑制持续性HCV感染。

原始出处:Kim SJ ,et al. Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation. Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177. [Epub ahead of print]

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1274577, encodeId=f43612e4577d1, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426736, encodeId=d9d71426e36bf, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429536, encodeId=fd7a142953692, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205336, encodeId=375a2053364b, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Jun 01 21:21:59 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204988, encodeId=af792049888a, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 01 00:15:59 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1274577, encodeId=f43612e4577d1, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426736, encodeId=d9d71426e36bf, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429536, encodeId=fd7a142953692, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205336, encodeId=375a2053364b, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Jun 01 21:21:59 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204988, encodeId=af792049888a, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 01 00:15:59 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-02 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1274577, encodeId=f43612e4577d1, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426736, encodeId=d9d71426e36bf, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429536, encodeId=fd7a142953692, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205336, encodeId=375a2053364b, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Jun 01 21:21:59 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204988, encodeId=af792049888a, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 01 00:15:59 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1274577, encodeId=f43612e4577d1, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426736, encodeId=d9d71426e36bf, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429536, encodeId=fd7a142953692, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205336, encodeId=375a2053364b, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Jun 01 21:21:59 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204988, encodeId=af792049888a, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 01 00:15:59 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 虈亣靌

    不错的方式,努力学习,刻苦专研,不断总结出来新经验。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1274577, encodeId=f43612e4577d1, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426736, encodeId=d9d71426e36bf, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429536, encodeId=fd7a142953692, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Fri Jun 02 06:57:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205336, encodeId=375a2053364b, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Jun 01 21:21:59 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204988, encodeId=af792049888a, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 01 00:15:59 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 130****4638

    学习了谢谢分享。

    0

相关资讯

Hepatology:积极治疗轻度肝纤维化,有效改善HCV预后

目前与丙型肝炎病毒(HCV)感染相关的长期前瞻性研究报道比较罕见,这对获取HCV的治疗手段也造成了困难。近日,发表于Hepatology杂志的一篇文章对HCV做了相关研究,以下是对该研究内容的简单介绍。

Hepatology:效果评估:给予DAA治疗失败的HCV患者 索非布韦-维帕他韦+利巴韦林24周

对于直接作用抗病毒(DAA)治疗失败的丙型肝炎病毒(HCV)患者的最佳再治疗策略目前仍不清楚。在本项多中心 开放标记的2阶段研究中,我们给予DAA治疗后未达到SVR的患者24周组合用药(索非布韦-维帕他韦(400mg / 100mg)+按重量调整的利巴韦林),并评估其有效性和安全性。这些患者先前的DAA治疗中,使用核苷酸类似物NS5B抑制剂索非布韦+NS5A抑制剂维帕他韦,包含或不含NS3 / 4

Clin Gastroenterol H:HCV患者抗病毒治疗后肝脏硬度降低程度如何?

在这项系统回顾和荟萃分析中,研究人员发现根除HCV感染(SVR)可以显著降低肝脏硬度,尤其是在基础炎症水平较高的患者或服用直接抗病毒药物的患者中。几乎一半的患者治疗前被认为存在晚期肝纤维化,基于VCTE,治疗后可以达到肝脏硬度低于9.5kPa。

Hepatology:评估DAA方案对伴有丙型肝炎的肝肾移植受者的安全性与有效性:结果来自HCV-TARGET研究

对于实体器官移植受者中的慢性HCV患者,给予直接作用抗病毒(DAA)方案(同时采用或不采用利巴韦林治疗)的临床试验之外的数据有限。近日美国学者发表研究性文章于Hepatology。试验使用从2014年1月1日至2016年2月15日期间,用DAA方案治疗的HCV-TARGET数据库(一项多中心纵向临床护理治疗队列)中肝移植(LT),肾移植(KT)和双肝肾移植受体(DLK),并评估其中DAA方案治疗的

KIDNEY INT:高丙型肝炎病毒载量和基因型2是慢性肾脏病的强预测因子!

因此,慢性HCV感染与CKD的风险增加有关。高HCV病毒载量和HCV基因型2是CKD较强的预测因子。

CCLM:基于三个不同HCV基因组区域的实时PCR对新cobas®HCV基因分型测试进行评估

丙型肝炎病毒(HCV)基因型的确定和丙型肝炎病毒亚型1a和1b的鉴定在抗HCV治疗开始前是强制性要求的。本研究的目的是评估最近推出的cobas®HCV GT测定(Roche)的性能,并将其与两种对照试验进行比较。